Reference entry · Single-chain H2 relaxin B-chain derivative
B7-33
Also known as: Relaxin-2 B-chain analog · RXFP1 biased agonist
- Class
- Single-chain H2 relaxin B-chain derivative
- Primary targets (literature)
- RXFP1 (relaxin family peptide receptor 1); biased pERK signaling
- Regulatory context
- Investigational research peptide only. No FDA approval. Native serelaxin clinical history does not extend to B7-33.
Overview
B7-33 is a minimized relaxin-2 analog designed as a biased RXFP1 agonist with anti-fibrotic activity in rodent organ models. Not FDA-approved; distinct from native two-chain relaxin.
Mechanism in research literature
Preferential pERK1/2 activation over cAMP at RXFP1 in endogenous-expression cell models; proposed anti-fibrotic signaling via MMP activation and AT2 receptor heterodimers.
Common research focus areas
- Cardiac and pulmonary fibrosis rodent models
- Biased agonism vs. native H2 relaxin cAMP profile
- Medicinal chemistry minimization of relaxin scaffold
- Sequence MS identity vs. native relaxin mislabeling
Full literature roundup
Read the cited research summary
A single-chain relaxin-2 B-chain analog and biased RXFP1 agonist. Anti-fibrotic rodent literature, signaling selectivity, and synthesis identity requirements.
B7-33 research roundup · 4 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.